Study type: In vivo/preclinical · Status: Verified against declared source
Adjunctive Thymosin Beta-4 Treatment Influences PMN Effector Cell Function during-Induced Corneal Infection.
Cells · 2021
Study scale: Previous work examining the therapeutic efficacy of adjunct thymosin beta 4 (Tβ4) to ciprofloxacin for ocular infectious disease has revealed markedly reduced inflammation (inflammatory mediators and innate immune cells) with increased activation of wound healing pathways.
Abstract only: Open source record
Product or molecular entity relationships
- Thymosin Beta-4 (TB500): Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
Not reported in the reviewed source.
Methods
Individual corneas were homogenized in RIPA buffer (Cell Signaling Technology, Danvers, MA, USA).
Scale or participants
Previous work examining the therapeutic efficacy of adjunct thymosin beta 4 (Tβ4) to ciprofloxacin for ocular infectious disease has revealed markedly reduced inflammation (inflammatory mediators and innate immune cells) with increased activation of wound healing pathways.
Key findings
Previous work examining the therapeutic efficacy of adjunct thymosin beta 4 (Tβ4) to ciprofloxacin for ocular infectious disease has revealed markedly reduced inflammation (inflammatory mediators and innate immune cells) with increased activation of wound healing pathways.
Limitations and uncertainty
Microbial keratitis is a sight-threatening infection of the cornea often resulting from ocular injury or extended contact lens wear [1,2].
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.